logo-loader
viewANGLE PLC

ANGLE PLC submits its flagship Parsortix liquid biopsy diagnostic to the FDA

ANGLE PLC (LON:AGL) (OTCQX:ANPCY) CEO Andrew Newland tells Proactive the company has submitted its patent-protected, flagship Parsortix liquid biopsy diagnostic for clearance to the FDA. 

Newland says this is a tremendous opportunity for ANGLE, as he says ANGLE is the first company to potentially get FDA clearance for its platform that harvests live circulating tumor cells (CTCs) from a patient's blood.

Quick facts: ANGLE PLC

Price: 50 GBX

AIM:AGL
Market: AIM
Market Cap: £86.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: BATM develops new diagnostic kit to detect coronavirus

Headlines from the Proactive UK newsroom. Medical device maker BATM (LON:BVC) says its bio-medical division has successfully developed a new diagnostics kit to detect coronavirus. The kit's also undergone testing by several central labs and hospitals that have now verified its ability to...

on 27/2/20

2 min read